Modeling tau neuropathology heterogeneity using LTs as quantitative phenotypes in a GWAS may provide substantial insight into biological pathways involved in PSP by affecting regional tau burden. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.